MX2021014868A - Oligonucleotidos y metodos de uso para el tratamiento de enfermedades neurologicas. - Google Patents
Oligonucleotidos y metodos de uso para el tratamiento de enfermedades neurologicas.Info
- Publication number
- MX2021014868A MX2021014868A MX2021014868A MX2021014868A MX2021014868A MX 2021014868 A MX2021014868 A MX 2021014868A MX 2021014868 A MX2021014868 A MX 2021014868A MX 2021014868 A MX2021014868 A MX 2021014868A MX 2021014868 A MX2021014868 A MX 2021014868A
- Authority
- MX
- Mexico
- Prior art keywords
- neurological diseases
- methods
- oligonucleotides
- treating neurological
- ftd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se describen secuencias de oligonucleótidos antisentido y métodos de uso para tratar enfermedades neurológicas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962856264P | 2019-06-03 | 2019-06-03 | |
US201962914252P | 2019-10-11 | 2019-10-11 | |
US201962949817P | 2019-12-18 | 2019-12-18 | |
PCT/US2020/035811 WO2020247419A2 (en) | 2019-06-03 | 2020-06-03 | Oligonucleotides and methods of use for treating neurological diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014868A true MX2021014868A (es) | 2022-03-25 |
Family
ID=73653367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014868A MX2021014868A (es) | 2019-06-03 | 2020-06-03 | Oligonucleotidos y metodos de uso para el tratamiento de enfermedades neurologicas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220333105A1 (es) |
EP (1) | EP3976010A4 (es) |
JP (1) | JP2022536085A (es) |
KR (1) | KR20220033472A (es) |
CN (1) | CN114555069A (es) |
AU (1) | AU2020288555A1 (es) |
BR (1) | BR112021024463A2 (es) |
CA (1) | CA3142526A1 (es) |
IL (1) | IL288574A (es) |
MX (1) | MX2021014868A (es) |
WO (1) | WO2020247419A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022517117A (ja) * | 2019-01-14 | 2022-03-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Stmn2レベルを回復させるための方法及び組成物 |
WO2022018155A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Lna oligonucleotides for splice modulation of stmn2 |
JP2023534557A (ja) | 2020-07-23 | 2023-08-09 | エフ. ホフマン-ラ ロシュ アーゲー | Rna結合タンパク質部位を標的とするオリゴヌクレオチド |
JP2024513237A (ja) * | 2021-04-06 | 2024-03-22 | メイズ セラピューティクス, インコーポレイテッド | Tdp-43プロテイノパチーを処置するための組成物及び方法 |
AU2022328401A1 (en) * | 2021-08-11 | 2024-02-22 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting stathmin 2 (stmn2) and uses thereof |
AU2022402929A1 (en) * | 2021-12-03 | 2024-06-13 | Quralis Corporation | Splice switcher antisense oligonucleotides with modified backbone chemistries |
GB202208384D0 (en) * | 2022-06-08 | 2022-07-20 | Ucl Business Ltd | Modified U7 snRNA construct |
GB202208387D0 (en) * | 2022-06-08 | 2022-07-20 | Ucl Business Ltd | Modified U7 snRNA construct |
WO2024124203A2 (en) * | 2022-12-09 | 2024-06-13 | Auttx, Llc | Targeted treatment of spliceopathy-induced neurological disorders |
US20240301447A1 (en) * | 2023-02-15 | 2024-09-12 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187545B1 (en) * | 2000-01-19 | 2001-02-13 | Isis Pharmaceuticals Inc. | Antisense modulation of pepck-cytosolic expression |
AU2002224787A1 (en) * | 2000-10-23 | 2002-05-06 | Mermaid Pharmaceuticals Gmbh | Method for temporally controlling antisense-mediated gene inactivation |
US20030104410A1 (en) * | 2001-03-16 | 2003-06-05 | Affymetrix, Inc. | Human microarray |
EP1815863A1 (en) * | 2006-02-03 | 2007-08-08 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of TLR3 agonists for the treatment of neurodegenerative disorders |
EP2134863B1 (en) * | 2007-03-13 | 2014-05-21 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis of type 1 diabetes |
KR101703695B1 (ko) * | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료 |
WO2012005898A2 (en) * | 2010-06-15 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof |
WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
WO2015051239A1 (en) * | 2013-10-03 | 2015-04-09 | The General Hospital Corporation | Methods for increasing neuronal survival |
US10538762B2 (en) * | 2014-10-14 | 2020-01-21 | The Board Of Regents Of The University Of Texas System | Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat |
EP3371328A2 (en) * | 2015-11-04 | 2018-09-12 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
CA3103429A1 (en) * | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
CN116034161A (zh) * | 2020-03-25 | 2023-04-28 | 哈佛学院校长同事会 | 用于恢复stmn2水平的方法和组合物 |
-
2020
- 2020-06-03 US US17/616,350 patent/US20220333105A1/en active Pending
- 2020-06-03 BR BR112021024463A patent/BR112021024463A2/pt unknown
- 2020-06-03 EP EP20818770.8A patent/EP3976010A4/en active Pending
- 2020-06-03 KR KR1020217043411A patent/KR20220033472A/ko unknown
- 2020-06-03 AU AU2020288555A patent/AU2020288555A1/en active Pending
- 2020-06-03 CN CN202080054507.9A patent/CN114555069A/zh active Pending
- 2020-06-03 WO PCT/US2020/035811 patent/WO2020247419A2/en unknown
- 2020-06-03 MX MX2021014868A patent/MX2021014868A/es unknown
- 2020-06-03 CA CA3142526A patent/CA3142526A1/en active Pending
- 2020-06-03 JP JP2021571911A patent/JP2022536085A/ja active Pending
-
2021
- 2021-12-01 IL IL288574A patent/IL288574A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020247419A3 (en) | 2021-01-14 |
US20220333105A1 (en) | 2022-10-20 |
JP2022536085A (ja) | 2022-08-12 |
CN114555069A (zh) | 2022-05-27 |
KR20220033472A (ko) | 2022-03-16 |
IL288574A (en) | 2022-02-01 |
BR112021024463A2 (pt) | 2022-03-08 |
EP3976010A2 (en) | 2022-04-06 |
AU2020288555A1 (en) | 2022-01-20 |
EP3976010A4 (en) | 2023-08-02 |
WO2020247419A2 (en) | 2020-12-10 |
CA3142526A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014868A (es) | Oligonucleotidos y metodos de uso para el tratamiento de enfermedades neurologicas. | |
MX358603B (es) | Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen. | |
MX2021012126A (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central. | |
WO2010129746A3 (en) | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp | |
WO2010065671A3 (en) | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf | |
MX2011009752A (es) | Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1). | |
WO2011150005A3 (en) | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 | |
WO2010138806A3 (en) | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene | |
WO2011019815A3 (en) | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) | |
WO2007044468A3 (en) | Method to treat flavivirus infection with sirna | |
WO2012009402A3 (en) | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg | |
WO2008154482A3 (en) | Sirna compositions and methods of use in treatment of ocular diseases | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
MX339820B (es) | Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1. | |
WO2011079261A3 (en) | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf | |
WO2011091390A3 (en) | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 | |
WO2011127337A3 (en) | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 | |
WO2011103528A3 (en) | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 | |
WO2011146675A3 (en) | Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2 | |
WO2011038205A3 (en) | Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh | |
WO2011017516A3 (en) | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) | |
EP2633052A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH THE INTERFERON 1-RELATED DEVELOPMENT REGULATOR (IFRD1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF IFRD1 | |
WO2010135329A3 (en) | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor | |
WO2011143640A3 (en) | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 | |
AR067395A1 (es) | Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular |